SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "L773:0250 7005 OR L773:1791 7530 "

Sökning: L773:0250 7005 OR L773:1791 7530

Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Alanazi, Sultan, et al. (författare)
  • Histone Methyltransferase Inhibition Has a Cytotoxic Impact on Transformed Mast Cells : Implications for Mastocytosis
  • 2020
  • Ingår i: ; 40:5, s. 2525-2536
  • Tidskriftsartikel (refereegranskat)abstract
    • Background/Aim: Mast cell transformation, as manifested in mastocytosis, can be a serious condition for which there are limited therapeutic options. Mastocytosis cells can be sensitive to histone deacetylase (HDAC) inhibitors, but their sensitivity to other histone-modifying enzymes has not been assessed. Here we addressed this issue.Materials and Methods: Inhibitors of histone methyl transferases, histone demethylases, histone acetyl transferases and HDACs were tested for their effects on growth, viability, caspase-3 activation and annexin V/DRAQ7 staining in transformed mast cells.Results: Transformed mast cells underwent cell death in response to histone methyl transferase and HDAC inhibition, but were not sensitive to histone demethylase or histone acetyl transferase inhibition. Histone methyl transferase inhibition led to cell death with characteristics of apoptosis, as judged by caspase-3 activation. However, DNA fragmentation was not apparent and Annexin V+/DRAQ7(-) cells were not predominant, suggesting a type of cell death differing from classical apoptosis.Conclusion: Histone methyl transferase inhibition could be developed as a novel regimen for targeting mastocytosis.
  •  
2.
  • Almlöv, Karin, et al. (författare)
  • MRI Lymph Node Evaluation for Prediction of Metastases in Rectal Cancer
  • 2020
  • Ingår i: Anticancer Research. - : International Institute of Anticancer Research. - 0250-7005 .- 1791-7530. ; 40:5, s. 2757-2763
  • Tidskriftsartikel (refereegranskat)abstract
    • Aim: To explore whether the size and characteristics of the largest regional lymph node in patients with rectal cancer, based on magnetic resonance imaging (MRI), following neoadjuvant therapy and before surgery, is able to identify patients at high risk of developing metachronous metastases. Patients and Methods: A retrospective case-control study with data from the Swedish Colo-Rectal Cancer Registry. Forty patients were identified with metachronous metastases (M+), and 40 patients without metastases (M0) were matched as controls. Results: Patients with M+ disease were more likely to have a regional lymph node measuring >= 5 mm than patients with M0. (87% vs. 65%, p=0.02). There was also a significant difference between the groups regarding the presence of an irregular border of the largest lymph node (68% vs. 40%, p=0.01). Conclusion: Lymph nodes measuring >= 5 mm with/without displaying irregular borders at MRI performed after neoadjuvant therapy emerged as risk factors for metachronous metastases in patients with rectal cancer. Intensified follow-up programmes may be indicated in these patients.
  •  
3.
  •  
4.
  • Andreasson, Hakan, et al. (författare)
  • Histopathological Classification of Pseudomyxoma Peritonei and the Prognostic Importance of PINCH Protein
  • 2012
  • Ingår i: Anticancer Research. - : International Institute of Anticancer Research (IIAR). - 0250-7005 .- 1791-7530. ; 32:4, s. 1443-1448
  • Tidskriftsartikel (refereegranskat)abstract
    • Aim: The aims of this study were i) to assess a new and more detailed histopathological classification and to analyze concordance between pathologists in the histopathological classification of pseudomyxoma peritonei (PMP); ii) to analyze the expression in the stroma of the particularly interesting new cysteine-histidine (PINCH) protein and its prognostic importance in PMP. Materials and Methods: Surgical specimens from 81 patients, classified according to the Ronnett et al histopathological classification were compared to a new system with four groups ranging from indolent to aggressive growth patterns. PINCH protein expression was analyzed and was related to clinical variables. Results: The new four-group classification provided better prognostic information than the classification according to Ronnett et al. (p=0.04). Expression of the PINCH protein in the stroma was found in 83% of the cases and was associated with high tumor burden (p=0.002) and a poor prognosis (p=0.04). Conclusion: The proposed new PMP classification system may provide additional prognostic information. PINCH protein is expressed in PMP and has prognostic information.
  •  
5.
  • Asklund, Thomas, et al. (författare)
  • Synergistic Killing of Glioblastoma Stem-like Cells by Bortezomib and HADC Inhibitors.
  • 2012
  • Ingår i: Anticancer Research. - 0250-7005 .- 1791-7530. ; 32:7, s. 2407-2413
  • Tidskriftsartikel (refereegranskat)abstract
    • Background: The malignant brain tumour glioblastoma is a devastating disease that remains a therapeutic challenge. Materials and Methods: Effects of combinations of the US Food and Drug Administation (FDA) approved proteasome inhibitor bortezomib and the histone deacetylase (HDAC) inhibitors vorinostat, valproic acid and sodium phenylbutyrate were studied on primary glioblastoma stem cell lines and conventional glioblastoma cell lines. Cell survival, proliferation and death were analyzed by fluorometric microculture cytotoxicity assay (FMCA), propidium iodide labeling and flow cytometry, and cell cloning through limiting dilution and live-cell bright-field microscopy. Results: Bortezomib and the HDAC inhibitors showed synergistic cell killing at clinically relevant drug concentrations, while the conventional cell lines cultured in serum-containing medium were relatively resistant to the same treatments. Conclusion: These findings of synergistic glioblastoma stem cell killing by bortezomib and three different FDA-approved HDAC inhibitors confirm and expand previous observations on co-operative effects between these classes of drugs.
  •  
6.
  • Asklund, Thomas, et al. (författare)
  • Synergistic killing of Glioblastoma Stem-like cells by Bortezomib and HDAC Inhibitors
  • 2012
  • Ingår i: Anticancer Research. - : International Institute of Anticancer Research. - 0250-7005 .- 1791-7530. ; 32:7 ; Special Issue, s. 2407-2413
  • Tidskriftsartikel (refereegranskat)abstract
    • Background: The malignant brain tumour glioblastoma is a devastating disease that remains a therapeutic challenge. Materials and Methods: Effects of combinations of the US Food and Drug Administation (FDA) approved proteasome inhibitor bortezomib and the histone deacetylase (HDAC) inhibitors vorinostat, valproic acid and sodium phenylbutyrate were studied on primary glioblastoma stem cell lines and conventional glioblastoma cell lines. Cell survival, proliferation and death were analyzed by fluorometric microculture cytotoxicity assay (FMCA), propidium iodide labeling and flow cytometry, and cell cloning through limiting dilution and live-cell bright-field microscopy. Results: Bortezomib and the HDAC inhibitors showed synergistic cell killing at clinically relevant drug concentrations, while the conventional cell lines cultured in serum-containing medium were relatively resistant to the same treatments. Conclusion: These findings of synergistic glioblastoma stem cell killing by bortezomib and three different FDA-approved HDAC inhibitors confirm and expand previous observations on co-operative effects between these classes of drugs.
  •  
7.
  • Backlin, Carin, et al. (författare)
  • Immunohistochemical expression of insulin-like growth factor 1 and its receptor in normal and neoplastic human adrenal cortex
  • 1995
  • Ingår i: Anticancer Research. - 0250-7005 .- 1791-7530. ; 15:6B, s. 2453-2459
  • Tidskriftsartikel (refereegranskat)abstract
    • BACKGROUND:Insulin-like growth factor 1 (IGF-1) may influence cellular growth, differentiation and secretion.MATERIAL AND METHODS:Cryosectioned normal human adrenal glands (n = 6), cortical adenoma (n = 21), and carcinoma (n = 17) were stained immunohistochemically for IGF-1 and its receptor, and human adrenocortical cancer cells expressing the receptor were analysed for influences on proliferation.RESULTS:Normal cortical parenchyma generally displayed faint IGF-1 reactivity and intracellular receptor staining. Similar labelling encompassed the adenomas, but only 6 of them were receptor reactive. IGF-1 expression was conspicuous in 11 carcinomas, and 6 of them displayed cell surface receptor reactivity. All aldosterone producing lesions were receptor antibody unreactive. Recombinant IGF-1 dose-dependently stimulated the cell proliferation, and this effect was reversed by the receptor antibody.CONCLUSION:IGF-1 may interact with function and proliferation of the human adrenal cortex with particular reference to cortical carcinomas lacking discernible aldosterone excess.
  •  
8.
  • Backman, Samuel, et al. (författare)
  • Detection of Somatic Mutations in Gastroenteropancreatic Neuroendocrine Tumors Using Targeted Deep Sequencing
  • 2017
  • Ingår i: Anticancer Research. - 0250-7005 .- 1791-7530. ; 37:2, s. 705-712
  • Tidskriftsartikel (refereegranskat)abstract
    • Mutations affecting the mechanistic target of rapamycin (MTOR) signalling pathway are frequent in human cancer and have been identified in up to 15% of pancreatic neuroendocrine tumours (NETs). Grade A evidence supports the efficacy of MTOR inhibition with everolimus in pancreatic NETs. Although a significant proportion of patients experience disease stabilization, only a minority will show objective tumour responses. It has been proposed that genomic mutations resulting in activation of MTOR signalling could be used to predict sensitivity to everolimus.PATIENTS AND METHODS: Patients with NETs that underwent treatment with everolimus at our Institution were identified and those with available tumour tissue were selected for further analysis. Targeted next-generation sequencing (NGS) was used to re-sequence 22 genes that were selected on the basis of documented involvement in the MTOR signalling pathway or in the tumourigenesis of gastroenterpancreatic NETs. Radiological responses were documented using Response Evaluation Criteria in Solid Tumours.RESULTS: Six patients were identified, one had a partial response and four had stable disease. Sequencing of tumour tissue resulted in a median sequence depth of 667.1 (range=404-1301) with 1-fold coverage of 95.9-96.5% and 10-fold coverage of 87.6-92.2%. A total of 494 genetic variants were discovered, four of which were identified as pathogenic. All pathogenic variants were validated using Sanger sequencing and were found exclusively in menin 1 (MEN1) and death domain associated protein (DAXX) genes. No mutations in the MTOR pathway-related genes were observed.CONCLUSION: Targeted NGS is a feasible method with high diagnostic yield for genetic characterization of pancreatic NETs. A potential association between mutations in NETs and response to everolimus should be investigated by future studies.
  •  
9.
  •  
10.
  • Blomberg, Carl, et al. (författare)
  • Randomized Trials of Systemic Medically-treated Malignant Mesothelioma : A Systematic Review.
  • 2015
  • Ingår i: Anticancer Research. - 0250-7005 .- 1791-7530. ; 35:5
  • Tidskriftsartikel (refereegranskat)abstract
    • Malignant pleural mesothelioma (MPM) is a rare but aggressive malignancy mainly localized to the pleura. Malignant mesothelioma grows highly invasive into surrounding tissue and has a low tendency to metastasize. The median overall survival (OS) of locally advanced or metastatic disease without treatment is 4-13 months but, during recent years, improvement in survival has been achieved since treatment for patients with mesothelioma has improved with better palliative care, systemic medical treatment, surgery and improved diagnostics methods. The present review aims at describing available data from randomized trials considering systemic medical treatment for this patient category.
  •  
Skapa referenser, mejla, bekava och länka
Typ av publikation
tidskriftsartikel (550)
konferensbidrag (27)
forskningsöversikt (17)
Typ av innehåll
refereegranskat (556)
övrigt vetenskapligt (38)
Författare/redaktör
Rubio, CA (90)
Dalianis, T (27)
Bergqvist, M. (16)
Ramqvist, T (16)
Hultborn, Ragnar, 19 ... (15)
Strang, P (15)
visa fler...
Munck-Wikland, E (15)
Bergqvist, Michael (14)
Brodin, O (13)
Andersson, Roland (12)
Henriksson, Roger (12)
Brattstrom, D (12)
Nilsson, S (10)
Glimelius, B (10)
Schmidt, PT (10)
Wagenius, G. (10)
Hellberg, Dan (10)
Ansari, Daniel (10)
Ekman, Simon (9)
Befrits, R. (9)
Xu, Ning (9)
Borgfeldt, Christer (9)
Nasman, A (9)
Ranstam, J (9)
Larsson, A. (8)
Tribukait, B (8)
Lewensohn, R. (8)
Willen, Roger (8)
Auer, G (8)
Edgren, M. (8)
Willen, R. (8)
Edler, D (8)
Hesselius, P (8)
Naredi, Peter, 1955 (7)
Lindblom, A (7)
Nilsson, A (7)
Linder, S (7)
Stendahl, Ulf (7)
Jaramillo, E (7)
Bauden, Monika (7)
Lindahl, B (7)
Marquez, M (7)
Ranstam, Jonas (7)
Lindholm, J. (7)
Toma-Dasu, Iuliana (7)
Toma-Dasu, I (7)
Persson, Jenny L. (7)
Lindahl, Bengt (7)
Lindquist, David (7)
Ragnhammar, P (7)
visa färre...
Lärosäte
Karolinska Institutet (286)
Uppsala universitet (99)
Lunds universitet (98)
Umeå universitet (57)
Göteborgs universitet (55)
Linköpings universitet (32)
visa fler...
Jönköping University (13)
Örebro universitet (12)
Kungliga Tekniska Högskolan (8)
Stockholms universitet (8)
Chalmers tekniska högskola (3)
Högskolan Kristianstad (1)
swepub_uni:mau_t (1)
Högskolan i Skövde (1)
Södertörns högskola (1)
Högskolan i Halmstad (1)
visa färre...
Språk
Engelska (593)
Odefinierat språk (1)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (239)
Naturvetenskap (12)
Samhällsvetenskap (1)

År

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy